Notice of Prize Competition for the DataWorks! - NIH FASEB Challenge
The purpose of the 2023 DataWorks! Prize is to incentivize creativity in developing best practices and strategies to share data and to further the NIH’s Policy for Data Management and Sharing. The prize will recognize and reward exceptional data practices in biological and biomedical research labs during the active phase of research that enable robust data sharing and reuse and create a library of best practice methods that can be used by the broader research community.
The challenge seeks best practice “recipes” that advance biological and biomedical research activities, with a focus on practices enabling robust data management during the research process. Participants will submit their data sharing/reuse best practice recipes in a form that can be used by an audience of their peers, such as a teaching resource or tool for active data management. In this way, the 2023 prize will collate a rich set of best practices recipes and interactive resources that can be used by the research community to more easily and successfully manage, share, and reuse data.
The 2023 DataWorks! Prize will include up to 16 team awards. Submissions will undergo an expert review, with final awards selected by a panel of NIH judges. Winning teams will be recognized with a cash prize and will be invited to participate in future DataWorks! Program opportunities. Non-Monetary honorable mentions will also be awarded.
- PHS 2023-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). (PA-23-230) This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2023-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA).
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development (SB1, Clinical Trial Not Allowed) (PAR-23-219) The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award.
- Department of Defense Medical Research and Development Program (DMRDP) Trauma Immunology Research Award. The immunological response to traumatic injuries has been studied over the years, but much remains unknown. Traumatic injuries initiate a chain of reactions with immune cells and modulators that, depending on various factors, could be advantageous or deleterious. Traumatic injuries can affect multiple organ systems and cell types, trigger the release of damage-associated molecular patterns (DAMPs) and other sterile inflammatory responses to hemorrhage and tissue damage, and subsequent responses involving pathogen-associated molecular patterns (PAMPs) from infectious agents. Traumatic injuries lead to barrier dysfunction and other complex pathologies locally and systematically. This Trauma Immunology program area seeks to advance military trauma research to address unsolved traumatic injury-associated immunology questions to include mechanisms and early-stage development of potential therapeutics..
- For email notification when CDMRP funding opportunities are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.
- For more information about the CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
- For more information on types of funding opportunities offered and application strategies review the CDMRP Webinar Series: https://cdmrp.health.mil/pubs/Webinars/webinar_series.
Upcoming Training Opportunities
- NERIS Workshop. Monday 9th October 2023 as a satellite Workshop of next ERPW in Dublin, Ireland. Workshop themes include radiological impact assessment including data, models, and techniques; protective actions, decision support and disaster informatics; holistic and inclusive framework for preparedness for emergency response and recovery; and new challenges for emergency preparedness, response, and recovery. The deadline for both registrations is July 31, 2023. Abstract deadline is extended to June 30, 2023. To register to the workshop, register first for ERPW, and then register with the form for the NERIS Workshop with the following links:
- Software tools for Triage of the Acute Radiation Syndrome (StTARS) 2023: A Practical Workshop. Oak Ridge, Tennessee, USA, November 7-11 , 2023. During this workshop, participants will learn about the purpose and function of software tools developed by scientific groups within NATO. These tools either allow an integrated estimation of dose (BAT, WinFRAT), or the prediction of ARS severity based on changes in blood cell counts (H-module) in the first days after an exposure to ionizing radiation. You will be introduced into these tools primarily by those who developed them, so that you will learn about their strengths and limitations.
ICRP 2023: 7th International Symposium of the System of Radiological Protection. November 6-9, 2023. Tokyo, Japan. The scientific program for ICRP 2023 consists of three days of oral and poster presentations, as well as access to a digital poster platform which will provide more options and opportunities to showcase your work and interact with attendees. ICRP 2023 is currently accepting abstract submissions for posters or pre-recorded video presentations. All accepted posters will be available online, but the number that can be displayed at the venue is limited. All accepted pre-recorded videos will be available online only. The call for abstracts is officially open! Abstracts can be submitted here.
Article: “Application of the cytokinesis-block micronucleus assay for high dose exposures using imaging flow cytometry: CBMN assay for high dose exposures using imaging flow cytometry”
Drs. David J Brenner, Helen C Turner, and colleagues investigate the application of the cytokinesis-block micronucleus assay for high dose exposures using imaging flow cytometry. [Cytogenet Genome Res. 2023 Aug 1. doi: 10.1159/000532124. Online ahead of print.]
Lindsay A Beaton-Green, Jessica M Mayenburg, Leonora Marro, Eman Hassan, Sarita Cuadros Sanchez, Riham Darwish, Sylvie Lachapelle, Nadine Adam, Julie J Burtt, Cyndi Van Den Hanenberg, Matthew A Rodrigues, Qi Wang, David J Brenner, Helen C Turner, Ruth Wilkins
“Application of the cytokinesis-block micronucleus assay for high dose exposures using imaging flow cytometry: CBMN assay for high dose exposures using imaging flow cytometry”
- Assistant/Associate Professor of Pharmaceutical Sciences. University of Arkansas for Medical Sciences - Little Rock, AR. The University of Arkansas for Medical Sciences (UAMS) College of Pharmacy invites applications for a 12-month, tenure-track faculty position at the rank of assistant, associate, or full professor in the Department of Pharmaceutical Sciences. The faculty member will develop an independent research program in an area of biomedical or pharmaceutical sciences that is in line with or complements current research laboratories in the department and UAMS. While the primary focus of this position is scholarship, commitment to education activities and service to the College, University, and profession are also expected. Candidates with research programs in an area of cancer research, including but not limited to cancer (molecular) biology, radiation biology, development of novel cancer therapeutics, cancer immunology, the tumor microenvironment, or the study of effects of cancer therapy on normal (non-cancer) tissues are especially encouraged to apply. Academic rank will be commensurate with experience.